FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations - Wikidata - awgldk - TriplyDB

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

http://www.wikidata.org/entity/Q28289859

about

Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis Post-remission therapy for acute myeloid leukemia Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.Molecular therapy for acute myeloid leukaemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell death Microenvironmental hypoxia regulates FLT3 expression and biology in AML.All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.Inhibition of FLT3 in AML: a focus on sorafenib.High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: A prospective pilot study from India.Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia.Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles.Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.Sunitinib effectively reduces clonogenic acute myeloid leukemia cells in vitro.Advances in targeted therapy for acute myeloid leukaemia.Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?Selective inhibition of the myeloid Src-family kinase Fgr potently suppresses AML cell growth in vitro and in vivo.

P2860

Q26797245-50D532C1-F09C-4577-9E97-DA3F691B87AC Q26995867-4BD68B3A-0FE2-4E12-B861-D589A29D169D Q33572303-FB530064-D8B2-4709-917E-F593628D356F Q33886530-41033F18-25B8-49EF-8C8C-94AAA7F14394 Q33925672-5D377C53-6A4C-4541-A88E-3D4CE9C13B5B Q33943277-CAAEA47C-5D8A-4F67-823C-7DA7418D5556 Q34158454-9A288285-89E7-4ABE-A865-F9AE9FEB0FE9 Q34772229-E0F14638-6D30-48F1-806B-E24CCB5A647A Q35224437-1E2E215A-4BE3-4918-969E-714E57746497 Q35560182-F4DDBEE2-AA17-40A2-976B-B2C01FA7D675 Q35796826-50FFDAED-1E46-4E74-89AE-2D12124E564C Q36014637-31C274A2-0A98-4441-9039-700C6687FAD1 Q36329436-B7957426-422D-4696-882F-CA042BCCF7A4 Q36989582-C5F70ACB-B8B2-4C23-B519-591CA662DA6F Q37037268-4B16916D-2FB9-4517-BAA8-CF68E49628E6 Q37699211-2467CC92-9E36-4BE5-86D9-15CEC6B9EC4B Q38216649-CB3CC98A-7482-44E6-A1C2-0D8B02511B5B Q38285175-E4D467C6-8CBE-481E-B440-B011F838E6C9 Q38381981-6E9A7FE9-1B57-43E5-A02A-4F4A744A327D Q38494659-B61E2F72-3292-4FA2-8FEC-928DF34420DA Q38720331-B29F1F2A-87CA-40D4-9472-D1A8A8A8A4AE Q38857067-9B344240-D28C-4126-8037-A9596104C3AC Q38989349-7A094725-FFEC-402B-BB48-6443AD2F4B17 Q39283692-330B3970-EBDC-4528-A232-7466DACE3851 Q40985734-17164D5F-B9E0-4887-9A9B-68070AEB987D Q41071486-EF383143-4147-4FBF-B5B4-16F04F4EF72B Q41708770-0FB41794-7F12-42FC-A603-74A449F99A3E Q41818692-D4C17144-A69E-4655-86FA-0E30D0F8B956 Q42385341-27BBCE05-3FB8-420E-9F62-BD84ECB45296 Q42979880-332E81F4-F590-4EE3-88CD-B9BF2C393972 Q46065833-CDB82565-9895-4EFA-8351-FB00A81FD4BA Q48204144-33625E3F-B362-4412-940E-5679B64F22AE Q48224336-FAE9756D-FFD9-4C81-9D9C-5B120FC4E743 Q54109758-94A4C527-CF49-4D25-BBA0-B117419E2319

P2860

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

http://www.wikidata.org/entity/Q28289859

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@ast

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@en

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@nl

type

label

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@ast

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@en

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@nl

prefLabel

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@ast

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@en

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@nl

P1433

Q28289859-9EACAB14-DB09-4AC0-AD89-88292F791BE8

P1476

Q28289859-9619B8F0-8C8E-4944-90B6-53F9F79A151F

P2093

Q28289859-33AD0581-7F40-4CBC-B6B4-5B096BE0E7DA

Q28289859-F6575DBC-5A98-4227-9E6A-87D8E7590F3E

P2860

Q28289859-0003E191-7618-45C4-BFC3-13FC6ABCDBD1

Q28289859-033F0CDE-232E-44E2-9F7E-5870BED59E9E

Q28289859-0CEB9986-78CC-47AF-94BF-4303B5E4F495

Q28289859-11963B99-2721-45F3-9B90-A8ED72F4F9F6

Q28289859-16F27605-E54B-4D36-B2DF-A8DA8EAB76DE

Q28289859-1C6A901F-9DFE-4D5B-B551-B31D0D9C78AB

Q28289859-1F5081CA-993E-49A5-A862-67D9654BFFA1

Q28289859-1F65DC3F-0C55-4E50-A8D2-8FF0AB1EEC70

Q28289859-29A3CB18-C826-45B2-A8AA-D4B6C0E516AE

Q28289859-2BB5C0AF-4E2E-47B0-A3C2-0B21B478A171

P304

Q28289859-6F738DA1-0F79-4669-B7F8-B41F39023B1D

P31

Q28289859-3C46A360-3D64-47CC-B805-839CAE67289C

P3181

Q28289859-CD5489B9-020D-489D-985D-7AD19CD13080

P356

Q28289859-632E6E91-6E12-4E68-96CD-71534E3C5307

P407

Q28289859-8E9B539A-D2F3-4F8D-9C3E-0B3FA15B8E01

P433

Q28289859-1501B9D7-989C-4047-92C4-1B826FF72CF9

P478

Q28289859-6EEA8AA3-8345-48AD-883F-27E9AA27515B

P577

Q28289859-A14B53A2-F73B-40AD-A5AC-A55D1CD52BB7

P698

Q28289859-9496AFD0-3208-4711-B180-D0A559D53472

P921

Q28289859-023AEAD3-A185-4ABD-9B8F-3DE579A68860

P932

Q28289859-84C896EE-E747-4870-B0EA-09F7080CBF15

P3181

P356

10428194.2013.800198

P1433

Leukemia & Lymphoma

P1476

FLT3 tyrosine kinase inhibitor ...... l implications and limitations

@en

P2093

Mark J Levis

http://www.w3.org/2001/XMLSchema#string

Sabine Kayser

http://www.w3.org/2001/XMLSchema#string

P2860

Recurring mutations found by sequencing an acute myeloid leukemia genome

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

P304

243-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4868525

http://www.w3.org/2001/XMLSchema#string

P356

10.3109/10428194.2013.800198

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23631653

http://www.w3.org/2001/XMLSchema#string

P921

P932

4333682

http://www.w3.org/2001/XMLSchema#string